Related Experiment Video
Updated: Apr 25, 2026
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.8K
[Multi-factor retrospective study in 91 small cell lung cancer patients]
Ying Liu1, Jing Zhu1, Xianhong Liu1
1Department of Medical Oncology, Jilin Provincial Tumor Hospital, Changchun 130012, China.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|August 19, 2014
Summary
Prognostic factors for limited-disease small cell lung cancer (SCLC) include TNM stage and treatment patterns. Early radiation therapy may improve survival in advanced stages of SCLC.
Area of Science:
- Oncology
- Medical Research
Context:
- Small cell lung cancer (SCLC) has a poor prognosis despite advancements in chemotherapy and radiation.
- Limited-disease SCLC (LD-SCLC) requires identification of prognostic factors to improve patient outcomes.
Purpose:
- To investigate the correlation between treatment modalities, TNM stage, and prognosis in LD-SCLC patients.
- To identify significant prognostic factors for survival in LD-SCLC.
Summary:
- Retrospective analysis of 91 LD-SCLC patients (2006-2012) staged according to the 7th edition TNM classification.
- Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier and Cox proportional hazards models.
- TNM stage, radiation therapy patterns, and pre-radiation chemotherapy cycles were significant prognostic factors.
Impact:
- TNM staging and treatment strategies, including timing of radiation, are crucial for predicting survival in LD-SCLC.
- Findings suggest TNM stage is a beneficial prognostic factor for LD-SCLC treatment.
- Further investigation into the optimal timing of radiation therapy for Stage IIIa and IIIb LD-SCLC is warranted.
